{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"From the European Hematology Association 2010 Congress: For Patients with Follicular Lymphoma, Rituximab Maintenance Therapy Cuts Risk of Recurrence in Half (Phase III PRIMA Study) ","description":"Speaking at the meeting in Barcelona, Gilles Salles of the University  of Lyon discusses the results showing that patients who had achieved remissions  after immunochemotherapy had only half the risk of recurrence if they also  received rituximab maintenance therapy for two years compared with patients who  did not.","author_name":"OT Broadcast News","author_url":"http:\/\/www.oncology-times.com","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/1110572\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/item\/1110572"}